PDS Biotechnology Corp. PDSB
NASDAQ · United States · Health Technology
$0.7507+0.01 (+1.05%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.
39.3 months median overall survival in first-line (1L) R/M immune checkpoint inhibitor naïve patients Company continues to prioritize PDS0301 in metastatic colorectal cancer (mCRC) while pursuing partnership strategy for PDS0101 PRINCETON, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced the publication
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The latest update cuts the fair value price target for PDS Biotechnology from US$5.75 to US$4.75, signaling a more conservative valuation anchor for the stock. Analysts link this change to a mix of optimism around the refocused emphasis on PDS0301 and caution about funding needs, execution risks, and the structure of the Nant led financing. As you read on, you will see how these moving pieces shape the evolving story around PDS Biotechnology and what to watch next. Stay updated as the Fair...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.